Encore Vision Overview

  • Year Founded
  • 2007

Year Founded

  • Status
  • Acquired/​Merged

  • Latest Deal Type
  • M&A

  • Latest Deal Amount
  • $456M

Encore Vision General Information

Description

Developer of ophthalmic therapeutics to treat the eye condition presbyopia. The company provides an eye drop treatment designed to reduce eye lens stiffness and make the lens less viscous to restore flexibility, allowing the lens to thicken in the center during an attempt to focus on nearby objects, enabling patients to recover sight.

Contact Information

Ownership Status
Acquired/Merged
Financing Status
Formerly VC-backed
Corporate Office
  • 1120 South Freeway
  • Suite 118
  • Fort Worth, TX 76104
  • United States
+1 (817)
Primary Industry
Pharmaceuticals
Acquirer
Vertical(s)
Corporate Office
  • 1120 South Freeway
  • Suite 118
  • Fort Worth, TX 76104
  • United States
+1 (817)

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Encore Vision Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
7. Merger/Acquisition 20-Jan-2017 $456M Completed Generating Revenue
6. Later Stage VC (Series C) 12-May-2016 Completed Clinical Trials - Phase 2
5. Later Stage VC (Series B1) 09-Feb-2015 Completed Product Development
4. Later Stage VC (Series B) 16-Sep-2014 Completed Product Development
3. Grant 01-Jan-2013 Completed Product Development
2. Accelerator/Incubator $1.92M Completed Startup
1. Early Stage VC (Series A) 10-Jun-2010 $1.92M $1.92M Completed Startup
To view Encore Vision’s complete valuation and funding history, request access »

Encore Vision Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series C
Series B1
Series B 38,000,000 $0.001000 8% $0.18 $0.18 1x $0.18 33.14%
Series A 24,828,813 $0.001000 8% $0.08 $0.08 1x $0.08 21.66%
To view Encore Vision’s complete cap table history, request access »

Encore Vision Patents

Encore Vision Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2018055572-A1 Lipoic acid choline ester compositions and methods to stabilize into pharmaceutically relevant drug products Inactive 23-Sep-2016
US-20220096434-A1 Lipoic acid choline ester compositions and methods to generate biocompatible ophthalmic formulations Inactive 24-Sep-2015
WO-2017053646-A1 Lipoic acid choline ester compositions and methods to generate biocompatible ophthalmic formulations Inactive 24-Sep-2015
AU-2015227307-A1 Lipoic acid choline ester compositions and methods of use Inactive 03-Mar-2014
WO-2015134510-A1 Lipoic acid choline ester compositions and methods of use Inactive 03-Mar-2014 A61K9/08
To view Encore Vision’s complete patent history, request access »

Encore Vision Former Investors (6)

Investor Name Investor Type Holding Investor Since Participating Rounds
Bios Partners Venture Capital Minority
GrowCo Capital Venture Capital Minority
Sea Purity Investments Family Office Minority
Steelhead Capital Management Family Office Minority
TechFW Accelerator/Incubator
You’re viewing 5 of 6 investors. Get the full list »

Encore Vision Acquisitions (1)

Encore Vision’s most recent deal was a Merger/Acquisition with Evermind (Electronic Equipment and Instruments). The deal was made on 01-Nov-2016.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
Evermind (Electronic Equipment and Instruments) 01-Nov-2016 Merger/Acquisition Electronic Equipment and Instruments
To view Encore Vision’s complete acquisitions history, request access »

Encore Vision FAQs

  • When was Encore Vision founded?

    Encore Vision was founded in 2007.

  • Where is Encore Vision headquartered?

    Encore Vision is headquartered in Fort Worth, TX.

  • What industry is Encore Vision in?

    Encore Vision’s primary industry is Pharmaceuticals.

  • Is Encore Vision a private or public company?

    Encore Vision is a Private company.

  • What is the current valuation of Encore Vision?

    The current valuation of Encore Vision is .

  • What is Encore Vision’s current revenue?

    The current revenue for Encore Vision is .

  • How much funding has Encore Vision raised over time?

    Encore Vision has raised $14.2M.

  • Who are Encore Vision’s investors?

    Bios Partners, GrowCo Capital, Sea Purity Investments, Steelhead Capital Management, and TechFW are 5 of 6 investors who have invested in Encore Vision.

  • When was Encore Vision acquired?

    Encore Vision was acquired on 20-Jan-2017.

  • Who acquired Encore Vision?

    Encore Vision was acquired by Novartis.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process